SCHEMBL11943574

SCHEMBL11943574

COc1ccc(Sc2c(N3CCN(S(=O)(=O)c4cccs4)CC3)cnn(C)c2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.57
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
PKM P14618 3/20 0.46
GAA P10253 2/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 2/20 0.43
USP2 O75604 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
JAK2 O60674 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GBA1 P04062 1/20 0.40
BACE1 P56817 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943014 0.88 MAPK1 (0.56) MAPK1MAPTSMN1; SMN2PKMGAA
SCHEMBL11943575 0.85 PKM (0.51) MAPTSMN1; SMN2PKMGAATSHR
SCHEMBL11943561 0.79 MTOR (0.42) MAPTPKMGAATSHRCYP2C19
SCHEMBL11943573 0.76 PKM (0.47) MAPTSMN1; SMN2PKMGAATSHR
SCHEMBL11943052 0.75 MAPK1 (0.52) MAPK1MAPTSMN1; SMN2PKMGAA
SCHEMBL11943053 0.75 SMN1; SMN2 (0.52) MAPK1MAPTSMN1; SMN2PKMCYP2C9
SCHEMBL11943096 0.75 ALDH1A1 (0.55) MAPTSMN1; SMN2PKMGAATSHR
SCHEMBL11945000 0.73 MAPT (0.48) MAPK1MAPTPKMGAATSHR
SCHEMBL13305045 0.73 KMT2A (0.50) MAPK1MAPTSMN1; SMN2PKMGAA
SCHEMBL11943016 0.73 ALDH1A1 (0.51) MAPTSMN1; SMN2PKMGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPK1 1289/4885MAPT 2295/4885SMN1; SMN2 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.